403793-52-2Relevant academic research and scientific papers
BIS HETEROARYL INHIBITORS OF PRO-MATRIX METALLOPROTEINASE ACTIVATION
-
, (2012/06/01)
This invention relates to thiazole I and its therapeutic and prophylactic uses, wherein the variables A, Q, J, R1, R3, and R5 are defined in the specification. Disorders treated and/or prevented include rheumatoid arthritis.
METHODS OF INHIBITING PRO MATRIX METALLOPROTEINASE ACTIVATION
-
, (2012/12/13)
This invention relates to methods for preventing, treating or ameliorating an MMP9 and/or MMP13 mediated syndrome, disorder or disease comprising administering to a subject in need thereof an effective amount of a compound listed in the examples section of this specification, or a form, composition or medicament thereof. Disorders treated and/or prevented include rheumatoid arthritis.
Imidazoles: SAR and development of a potent class of cyclin-dependent kinase inhibitors
Anderson, Malcolm,Andrews, David M.,Barker, Andy J.,Brassington, Claire A.,Breed, Jason,Byth, Kate F.,Culshaw, Janet D.,Finlay, M. Raymond V.,Fisher, Eric,McMiken, Helen H.J.,Green, Clive P.,Heaton, Dave W.,Nash, Ian A.,Newcombe, Nicholas J.,Oakes, Sandra E.,Pauptit, Richard A.,Roberts, Andrew,Stanway, Judith J.,Thomas, Andrew P.,Tucker, Julie A.,Walker, Mike,Weir, Hazel M.
scheme or table, p. 5487 - 5492 (2009/05/30)
An imidazole series of cyclin-dependent kinase (CDK) inhibitors has been developed. Protein inhibitor structure determination has provided an understanding of the emerging structure activity trends for the imidazole series. The introduction of a methyl sulfone at the aniline terminus led to a more orally bioavailable CDK inhibitor that was progressed into clinical development.
Imidazolo-5-YL-2anilino-pyrimidines as agents for the inhibition of the cell proliffration
-
Page/Page column 39, (2010/02/05)
Compounds of the formula (I): wherein R1, R2, R3, R4, R5, R6, p, q, and n are as defined within and a pharmaceutically acceptable salts and in vivo hydrolysable esters are described. Also described are processes for their preparation and their use as medicaments, particularly medicaments for producing a cell cycle inhibitory (anti-cell-proliferation) effect in a warm-blooded animal, such as man.
